LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000490

A survey of treatment practices and burden of lymphoedema in Togo

Identifieur interne : 000490 ( PascalFrancis/Corpus ); précédent : 000489; suivant : 000491

A survey of treatment practices and burden of lymphoedema in Togo

Auteurs : Stephanie A. Richard ; Els Mathieu ; David G. A ; Yao K. Sodahlon

Source :

Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2007.

RBID : Pascal:07-0161388

Descripteurs français

Pascal (Inist)
- Lymphoedème, Filariose lymphatique, Angoisse anxiété, Etat dépressif, Surveillance, Enquête, Traitement, Pratique professionnelle, Togo, Epidémiologie, Morbidité, Homme, Santé publique, Trouble anxieux, Médecine tropicale, Maladie chronique.

English descriptors

KwdEn :
- Anxiety, Anxiety disorder, Chronic disease, Depression, Epidemiology, Human, Lymphatic filariasis, Lymphedema, Morbidity, Professional practice, Public health, Surveillance, Survey, Togo, Treatment, Tropical medicine.

Abstract

Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0035-9203`
A02	`01`			`@0 TRSTAZ`
A03		`1`		`@0 Trans. r. soc. trop. med. hyg.`
A05				`@2 101`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 A survey of treatment practices and burden of lymphoedema in Togo`
A11	`01`	`1`		`@1 RICHARD (Stephanie A.)`
A11	`02`	`1`		`@1 MATHIEU (Els)`
A11	`03`	`1`		`@1 A (David G.)`
A11	`04`	`1`		`@1 SODAHLON (Yao K.)`
A14	`01`			`@1 Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22 @2 Atlanta, GA 30341 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92 @2 Atlanta, GA 30333 @3 USA @Z 1 aut.`
A14	`03`			`@1 Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474 @2 Lomé @3 TGO @Z 4 aut.`
A20				`@1 391-397`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 3084 @5 354000145572100120`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 1/4 p.`
A47	`01`	`1`		`@0 07-0161388`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Transactions of the Royal Society of Tropical Medicine and Hygiene`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.
C02	`01`	`X`		`@0 002B12B04`
C02	`02`	`X`		`@0 002B05E03B4D`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Filariose lymphatique @5 02`
C03	`02`	`X`	`ENG`	`@0 Lymphatic filariasis @5 02`
C03	`02`	`X`	`SPA`	`@0 Filariasis linfática @5 02`
C03	`03`	`X`	`FRE`	`@0 Angoisse anxiété @5 03`
C03	`03`	`X`	`ENG`	`@0 Anxiety @5 03`
C03	`03`	`X`	`SPA`	`@0 Angustia ansiedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Etat dépressif @5 04`
C03	`04`	`X`	`ENG`	`@0 Depression @5 04`
C03	`04`	`X`	`SPA`	`@0 Estado depresivo @5 04`
C03	`05`	`X`	`FRE`	`@0 Surveillance @5 09`
C03	`05`	`X`	`ENG`	`@0 Surveillance @5 09`
C03	`05`	`X`	`SPA`	`@0 Vigilancia @5 09`
C03	`06`	`X`	`FRE`	`@0 Enquête @5 10`
C03	`06`	`X`	`ENG`	`@0 Survey @5 10`
C03	`06`	`X`	`SPA`	`@0 Encuesta @5 10`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 11`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 11`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 11`
C03	`08`	`X`	`FRE`	`@0 Pratique professionnelle @5 12`
C03	`08`	`X`	`ENG`	`@0 Professional practice @5 12`
C03	`08`	`X`	`SPA`	`@0 Práctica profesional @5 12`
C03	`09`	`X`	`FRE`	`@0 Togo @2 NG @5 13`
C03	`09`	`X`	`ENG`	`@0 Togo @2 NG @5 13`
C03	`09`	`X`	`SPA`	`@0 Togo @2 NG @5 13`
C03	`10`	`X`	`FRE`	`@0 Epidémiologie @5 14`
C03	`10`	`X`	`ENG`	`@0 Epidemiology @5 14`
C03	`10`	`X`	`SPA`	`@0 Epidemiología @5 14`
C03	`11`	`X`	`FRE`	`@0 Morbidité @5 15`
C03	`11`	`X`	`ENG`	`@0 Morbidity @5 15`
C03	`11`	`X`	`SPA`	`@0 Morbilidad @5 15`
C03	`12`	`X`	`FRE`	`@0 Homme @5 16`
C03	`12`	`X`	`ENG`	`@0 Human @5 16`
C03	`12`	`X`	`SPA`	`@0 Hombre @5 16`
C03	`13`	`X`	`FRE`	`@0 Santé publique @5 17`
C03	`13`	`X`	`ENG`	`@0 Public health @5 17`
C03	`13`	`X`	`SPA`	`@0 Salud pública @5 17`
C03	`14`	`X`	`FRE`	`@0 Trouble anxieux @5 19`
C03	`14`	`X`	`ENG`	`@0 Anxiety disorder @5 19`
C03	`14`	`X`	`SPA`	`@0 Trastorno ansiedad @5 19`
C03	`15`	`X`	`FRE`	`@0 Médecine tropicale @5 20`
C03	`15`	`X`	`ENG`	`@0 Tropical medicine @5 20`
C03	`15`	`X`	`SPA`	`@0 Medicina tropical @5 20`
C03	`16`	`X`	`FRE`	`@0 Maladie chronique @4 CD @5 96`
C03	`16`	`X`	`ENG`	`@0 Chronic disease @4 CD @5 96`
C03	`16`	`X`	`SPA`	`@0 Enfermedad crónica @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Nématodose`
C07	`01`	`X`	`ENG`	`@0 Nematode disease`
C07	`01`	`X`	`SPA`	`@0 Nematodosis`
C07	`02`	`X`	`FRE`	`@0 Helminthiase`
C07	`02`	`X`	`ENG`	`@0 Helminthiasis`
C07	`02`	`X`	`SPA`	`@0 Helmintiasis`
C07	`03`	`X`	`FRE`	`@0 Parasitose`
C07	`03`	`X`	`ENG`	`@0 Parasitosis`
C07	`03`	`X`	`SPA`	`@0 Parasitosis`
C07	`04`	`X`	`FRE`	`@0 Infection`
C07	`04`	`X`	`ENG`	`@0 Infection`
C07	`04`	`X`	`SPA`	`@0 Infección`
C07	`05`	`X`	`FRE`	`@0 Afrique @2 NG`
C07	`05`	`X`	`ENG`	`@0 Africa @2 NG`
C07	`05`	`X`	`SPA`	`@0 Africa @2 NG`
C07	`06`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`06`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`07`	`X`	`FRE`	`@0 Lymphatique pathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`07`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`08`	`X`	`FRE`	`@0 Trouble humeur @5 39`
C07	`08`	`X`	`ENG`	`@0 Mood disorder @5 39`
C07	`08`	`X`	`SPA`	`@0 Trastorno humor @5 39`
N21				`@1 106`

Format Inist (serveur)

NO :	PASCAL 07-0161388 INIST
ET :	A survey of treatment practices and burden of lymphoedema in Togo
AU :	RICHARD (Stephanie A.); MATHIEU (Els); A (David G.); SODAHLON (Yao K.)
AF :	Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22/Atlanta, GA 30341/Etats-Unis (1 aut., 2 aut., 3 aut.); The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92/Atlanta, GA 30333/Etats-Unis (1 aut.); Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474/Lomé/Togo (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Transactions of the Royal Society of Tropical Medicine and Hygiene; ISSN 0035-9203; Coden TRSTAZ; Royaume-Uni; Da. 2007; Vol. 101; No. 4; Pp. 391-397; Bibl. 1/4 p.
LA :	Anglais
EA :	Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.
CC :	002B12B04; 002B05E03B4D
FD :	Lymphoedème; Filariose lymphatique; Angoisse anxiété; Etat dépressif; Surveillance; Enquête; Traitement; Pratique professionnelle; Togo; Epidémiologie; Morbidité; Homme; Santé publique; Trouble anxieux; Médecine tropicale; Maladie chronique
FG :	Nématodose; Helminthiase; Parasitose; Infection; Afrique; Appareil circulatoire pathologie; Lymphatique pathologie; Trouble humeur
ED :	Lymphedema; Lymphatic filariasis; Anxiety; Depression; Surveillance; Survey; Treatment; Professional practice; Togo; Epidemiology; Morbidity; Human; Public health; Anxiety disorder; Tropical medicine; Chronic disease
EG :	Nematode disease; Helminthiasis; Parasitosis; Infection; Africa; Cardiovascular disease; Lymphatic vessel disease; Mood disorder
SD :	Linfedema; Filariasis linfática; Angustia ansiedad; Estado depresivo; Vigilancia; Encuesta; Tratamiento; Práctica profesional; Togo; Epidemiología; Morbilidad; Hombre; Salud pública; Trastorno ansiedad; Medicina tropical; Enfermedad crónica
LO :	INIST-3084.354000145572100120
ID :	07-0161388

Links to Exploration step

Pascal:07-0161388

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A survey of treatment practices and burden of lymphoedema in Togo</title>
<author><name sortKey="Richard, Stephanie A" sort="Richard, Stephanie A" uniqKey="Richard S" first="Stephanie A." last="Richard">Stephanie A. Richard</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathieu, Els" sort="Mathieu, Els" uniqKey="Mathieu E" first="Els" last="Mathieu">Els Mathieu</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="A, David G" sort="A, David G" uniqKey="A D" first="David G." last="A">David G. A</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sodahlon, Yao K" sort="Sodahlon, Yao K" uniqKey="Sodahlon Y" first="Yao K." last="Sodahlon">Yao K. Sodahlon</name>
<affiliation><inist:fA14 i1="03"><s1>Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474</s1>
<s2>Lomé</s2>
<s3>TGO</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0161388</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0161388 INIST</idno>
<idno type="RBID">Pascal:07-0161388</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000490</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A survey of treatment practices and burden of lymphoedema in Togo</title>
<author><name sortKey="Richard, Stephanie A" sort="Richard, Stephanie A" uniqKey="Richard S" first="Stephanie A." last="Richard">Stephanie A. Richard</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathieu, Els" sort="Mathieu, Els" uniqKey="Mathieu E" first="Els" last="Mathieu">Els Mathieu</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="A, David G" sort="A, David G" uniqKey="A D" first="David G." last="A">David G. A</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sodahlon, Yao K" sort="Sodahlon, Yao K" uniqKey="Sodahlon Y" first="Yao K." last="Sodahlon">Yao K. Sodahlon</name>
<affiliation><inist:fA14 i1="03"><s1>Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474</s1>
<s2>Lomé</s2>
<s3>TGO</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<title level="j" type="abbreviated">Trans. r. soc. trop. med. hyg.</title>
<idno type="ISSN">0035-9203</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Transactions of the Royal Society of Tropical Medicine and Hygiene</title>
<title level="j" type="abbreviated">Trans. r. soc. trop. med. hyg.</title>
<idno type="ISSN">0035-9203</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Anxiety disorder</term>
<term>Chronic disease</term>
<term>Depression</term>
<term>Epidemiology</term>
<term>Human</term>
<term>Lymphatic filariasis</term>
<term>Lymphedema</term>
<term>Morbidity</term>
<term>Professional practice</term>
<term>Public health</term>
<term>Surveillance</term>
<term>Survey</term>
<term>Togo</term>
<term>Treatment</term>
<term>Tropical medicine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Filariose lymphatique</term>
<term>Angoisse anxiété</term>
<term>Etat dépressif</term>
<term>Surveillance</term>
<term>Enquête</term>
<term>Traitement</term>
<term>Pratique professionnelle</term>
<term>Togo</term>
<term>Epidémiologie</term>
<term>Morbidité</term>
<term>Homme</term>
<term>Santé publique</term>
<term>Trouble anxieux</term>
<term>Médecine tropicale</term>
<term>Maladie chronique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0035-9203</s0>
</fA01>
<fA02 i1="01"><s0>TRSTAZ</s0>
</fA02>
<fA03 i2="1"><s0>Trans. r. soc. trop. med. hyg.</s0>
</fA03>
<fA05><s2>101</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A survey of treatment practices and burden of lymphoedema in Togo</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RICHARD (Stephanie A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MATHIEU (Els)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>A (David G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SODAHLON (Yao K.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22</s1>
<s2>Atlanta, GA 30341</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92</s1>
<s2>Atlanta, GA 30333</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474</s1>
<s2>Lomé</s2>
<s3>TGO</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>391-397</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>3084</s2>
<s5>354000145572100120</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0161388</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Transactions of the Royal Society of Tropical Medicine and Hygiene</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05E03B4D</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Filariose lymphatique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lymphatic filariasis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Filariasis linfática</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Depression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Surveillance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Surveillance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vigilancia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Enquête</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Survey</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Encuesta</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pratique professionnelle</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Professional practice</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Práctica profesional</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Togo</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Togo</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Togo</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Morbidité</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Morbidity</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Morbilidad</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Homme</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Human</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Hombre</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Public health</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Trouble anxieux</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Anxiety disorder</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Trastorno ansiedad</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Médecine tropicale</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Tropical medicine</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Medicina tropical</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Maladie chronique</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Chronic disease</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Enfermedad crónica</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Nématodose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nematode disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Nematodosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Helminthiase</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Helminthiasis</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Helmintiasis</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Parasitose</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Parasitosis</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Parasitosis</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Afrique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Africa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble humeur</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>39</s5>
</fC07>
<fN21><s1>106</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 07-0161388 INIST</NO>
<ET>A survey of treatment practices and burden of lymphoedema in Togo</ET>
<AU>RICHARD (Stephanie A.); MATHIEU (Els); A (David G.); SODAHLON (Yao K.)</AU>
<AF>Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, MS-F22/Atlanta, GA 30341/Etats-Unis (1 aut., 2 aut., 3 aut.); The Public Health Prevention Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mailstop E-92/Atlanta, GA 30333/Etats-Unis (1 aut.); Togo National Program to Eliminate Lymphatic Filariasis, Ministry of Health, BP 8474/Lomé/Togo (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene; ISSN 0035-9203; Coden TRSTAZ; Royaume-Uni; Da. 2007; Vol. 101; No. 4; Pp. 391-397; Bibl. 1/4 p.</SO>
<LA>Anglais</LA>
<EA>Lymphatic filariasis, a mosquito-borne parasitic disease, can lead to lymphoedema and elephantiasis. This study describes the results of a baseline survey of a lymphoedema morbidity management programme in Togo. A convenience sample of 188 people with lymphoedema was asked about symptoms, treatment preferences and quality of life. Those with higher stage lymphoedema were more likely to have experienced an acute attack (odds ratio = 1.9; P= 0.002). Although only 28.2% of those surveyed reported currently using any lymphoedema treatment, 80.3% had used treatments in the past, primarily traditional products (68.1%) and scarification (38.8%). Medication was the preferred treatment for acute attacks, both currently (73.1%) and in the past (61.7%). Patients reported difficulties performing activities such as walking to the field (44%) and carrying a heavy load (63%) as a result of their lymphoedema. Patients felt avoided by their family (17%) and their community (36%). Using the Duke Anxiety-Depression scale, over 70% of patients were found to be at high risk of depression and this risk increased with lymphoedema stage (P=0.04). The survey results demonstrate the need for a morbidity management programme that will increase the use of morbidity management techniques and decrease the physical and emotional burden of this disease.</EA>
<CC>002B12B04; 002B05E03B4D</CC>
<FD>Lymphoedème; Filariose lymphatique; Angoisse anxiété; Etat dépressif; Surveillance; Enquête; Traitement; Pratique professionnelle; Togo; Epidémiologie; Morbidité; Homme; Santé publique; Trouble anxieux; Médecine tropicale; Maladie chronique</FD>
<FG>Nématodose; Helminthiase; Parasitose; Infection; Afrique; Appareil circulatoire pathologie; Lymphatique pathologie; Trouble humeur</FG>
<ED>Lymphedema; Lymphatic filariasis; Anxiety; Depression; Surveillance; Survey; Treatment; Professional practice; Togo; Epidemiology; Morbidity; Human; Public health; Anxiety disorder; Tropical medicine; Chronic disease</ED>
<EG>Nematode disease; Helminthiasis; Parasitosis; Infection; Africa; Cardiovascular disease; Lymphatic vessel disease; Mood disorder</EG>
<SD>Linfedema; Filariasis linfática; Angustia ansiedad; Estado depresivo; Vigilancia; Encuesta; Tratamiento; Práctica profesional; Togo; Epidemiología; Morbilidad; Hombre; Salud pública; Trastorno ansiedad; Medicina tropical; Enfermedad crónica</SD>
<LO>INIST-3084.354000145572100120</LO>
<ID>07-0161388</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000490 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000490 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0161388
   |texte=   A survey of treatment practices and burden of lymphoedema in Togo
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

A survey of treatment practices and burden of lymphoedema in Togo

A survey of treatment practices and burden of lymphoedema in Togo

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri